{"id":8552,"date":"2024-01-21T05:30:30","date_gmt":"2024-01-21T05:30:30","guid":{"rendered":"http:\/\/insulinpharmacy.store\/?post_type=product&p=8552"},"modified":"2024-01-21T05:30:31","modified_gmt":"2024-01-21T05:30:31","slug":"lantus-solostar-pens-5-x-3-ml","status":"publish","type":"product","link":"https:\/\/insulinpharmacy.store\/product\/lantus-solostar-pens-5-x-3-ml\/","title":{"rendered":"Lantus Solostar Pens 5 x 3 ml"},"content":{"rendered":"

Basic Properties of Lantus Solostar Pen<\/h2>\n

Lantus Solostar pen is a long-acting insulin, human analog with an active substance insulin glargine (1 ml \u2013 100 units of insulin) and metacresol (m-cresol) \u2013 2.7 mg, zinc chloride \u2013 0.0626 mg (corresponds to 30 \u03bcg zinc), glycerol (85%) \u2013 20 mg, sodium hydroxide \u2013 up to pH 4.0, hydrochloric acid \u2013 up to pH 4.0, water d\/i \u2013 up to 1 ml as excipients for blood sugar control.<\/p>\n

The remedy is an injectable transparent, colorless, or almost colorless solution. Lantus Solostar insulin pen is prescribed in case of diabetes mellitus requiring insulin treatment in adults, adolescents, and children over 2 years of age.<\/p>\n

Dosage and Rules of Administration<\/h2>\n

Lantus SoloStar should be administered subcutaneously 1 time\/day at any time of the day, but every day at the same time. In patients with type 2 diabetes mellitus, the Lantus SoloStar pen can be used both as monotherapy and in combination with other hypoglycemic drugs. Target values for blood sugar levels, as well as the dose and timing of administration or administration of hypoglycemic drugs, should be determined and adjusted individually.<\/p>\n

A dose adjustment may also be required, for example, when weight gain occurs, lifestyle changes, the time of administration of the insulin dose is changed, or in other conditions that may increase the predisposition to the development of hypo- or hyperglycemia. Any changes in insulin dose should be done with caution and under medical supervision.<\/p>\n

Lantus SoloStar pen is administered as a subcutaneous injection. Lantus insulin glargine injection 100 units\/ml is not intended for intravenous administration. The long duration of action of insulin glargine is observed only when it is injected into the subcutaneous fat. Intravenous administration of the usual subcutaneous dose can cause severe hypoglycemia. Lantus SoloStar should be injected into the subcutaneous fatty tissue of the abdomen, shoulders, or thighs. The injection sites should be alternated with each new injection within the recommended areas for subcutaneous administration of the drug.<\/p>\n

To prevent infection, a pre-filled pen should be used by one patient only and should not be passed on to another person. Do not take Lantus injections by the same pen twice even if the needle has been changed.<\/p>\n

Common Side Effects<\/h2>\n

From the side of metabolism:<\/strong>\u00a0very common side effect \u2013 low blood sugar. Hypoglycemia, the most common adverse reaction with insulin therapy, can occur if the dose of insulin is too high compared to the need for it.<\/p>\n

From the immune system:<\/strong>\u00a0rarely \u2013 allergic reactions. Allergic reactions of an immediate-type to insulin are rare. Similar reactions to insulin (including insulin glargine) or excipients can be manifested by developing generalized skin reactions, angioedema, bronchospasm, lowering blood pressure, or shock and can thus become life-threatening.<\/p>\n

From the nervous system:<\/strong>\u00a0very rarely \u2013 dysgeusia.<\/p>\n

From the side of the organ of vision:<\/strong>\u00a0rarely \u2013 visual impairment; retinopathy.<\/p>\n

Skin and subcutaneous tissue disorders:<\/strong>\u00a0often \u2013 lipodystrophy (in 1-2% of patients). As with treatment with any other insulin preparations, lipodystrophy and\/or localized cutaneous amyloidosis may develop at the site of injection, slowing down the local absorption of insulin. Infrequently \u2013 lipoatrophy.<\/p>\n

From the musculoskeletal system:<\/strong>\u00a0very rarely \u2013 myalgia.<\/p>\n

General disorders and injection site reactions:<\/strong>\u00a0often \u2013 possible side effects include reactions at the site of injection (3-4%) (redness, pain, itching, urticaria, or inflammation); rarely sodium retention, edema.<\/p>\n

Important safety information for Lantus:<\/strong>\u00a0if you notice any long-lasting or serious side effects, apply to your doctor to get medical help right away.<\/p>\n

Contraindications<\/h2>\n